A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

Study Summary

This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).

Conditions

Hypertrophic Cardiomyopathy

Interventions / Drugs

EDG-7500 EDG-7500

View on ClinicalTrials.gov ↗

Sponsor

EWTX

Edgewise Therapeutics

Cardiomyopathy

D38/100

Study Details

Enrollment100 participants

Primary Completion—

Lead SponsorEdgewise Therapeutics, Inc.

Data Retrieved2026-04-11 04:13:37.458698+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.